MyFinsight
Home
Blog
About
Cash and cash
equivalents
$133,344K
(-28.53%↓ Y/Y)
Prepaid expenses and
other current assets
$8,736K
(35.86%↑ Y/Y)
Other receivables
$132K
(-81.92%↓ Y/Y)
Total current assets
$142,212K
(-26.68%↓ Y/Y)
Other non-current
assets
$4,769K
(-29.96%↓ Y/Y)
Operating right-of-use
asset
$4,555K
(-29.49%↓ Y/Y)
Property and equipment,
net
$2,686K
(-45.02%↓ Y/Y)
Total assets
$154,222K
(-27.29%↓ Y/Y)
Accumulated deficit
-$316,278K
(-77.59%↓ Y/Y)
Total liabilities and
stockholders equity...
$154,222K
(-27.29%↓ Y/Y)
Total stockholders
equity (deficit)
-$52,977K
(-177.27%↓ Y/Y)
Additional
paid-in-capital
$263,300K
(6.75%↑ Y/Y)
Common stock, 0.0001
par value...
$1K
(0.00%↑ Y/Y)
Total liabilities
$207,199K
(44.33%↑ Y/Y)
Long-term debt, net
$176,285K
(77.57%↑ Y/Y)
Total current
liabilities
$28,064K
(-27.93%↓ Y/Y)
Non-current portion of
operating lease liability
$2,850K
(-46.64%↓ Y/Y)
Accrued expenses
$15,773K
(-44.61%↓ Y/Y)
Accounts payable
$9,800K
(18.19%↑ Y/Y)
Current portion of
operating lease liability
$2,491K
(214.85%↑ Y/Y)
Back
Back
Balance Sheet
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)
source: myfinsight.com